Table 1.
Characteristics of study population. Values are numbers (percentages) unless stated otherwise
| Characteristics | Full sample (n=465 918) | Any warfarin use (n=71 533) | No warfarin use (n=394 385) | P value* |
|---|---|---|---|---|
| Mean (SD) age†, years | 74.6 (7.5) | 75.9 (7.3) | 74.4 (7.5) | <0.01 |
| Male sex | 196 758 (42.2) | 32 552 (45.5) | 164 206 (41.6) | <0.01 |
| White ethnicity | 352 409 (75.6) | 60 731 (84.9) | 291 678 (74.0) | <0.01 |
| Comorbidities†: | ||||
| Acute myocardial infarction or ischemic heart disease | 257 018 (55.2) | 50 678 (70.8) | 206 340 (52.3) | <0.01 |
| Alzheimer’s disease or dementia | 66 026 (14.2) | 10 151 (14.2) | 55 875 (14.2) | 0.871 |
| Asthma | 52 754 (11.3) | 9914 (13.9) | 42 840 (10.9) | <0.01 |
| Atrial fibrillation | 64 214 (13.8) | 35 458 (49.6) | 28 756 (7.29) | <0.01 |
| Cancer (breast, colorectal, endometrial, lung, or prostate) | 57 565 (12.4) | 10 509 (14.7) | 47 056 (11.9) | <0.01 |
| Chronic kidney disease | 109 280 (23.5) | 21 337 (29.8) | 87 943 (22.3) | <0.01 |
| Chronic obstructive pulmonary disease | 118 254 (25.4) | 24 189 (33.8) | 94 065 (23.9) | <0.01 |
| Congestive heart failure | 166 988 (35.8) | 40 675 (56.9) | 126 313 (32.0) | <0.01 |
| Depression | 114 473 (24.6) | 18 964 (26.5) | 95 509 (24.2) | <0.01 |
| Dyslipidemia | 357 962 (76.8) | 57 326 (80.1) | 300 636 (76.2) | <0.01 |
| Hypertension | 412 322 (88.5) | 66 007 (92.3) | 346 315 (87.8) | <0.01 |
| Osteoporosis | 57 094 (12.3) | 8999 (12.6) | 48 095 (12.2) | <0.01 |
| Rheumatoid arthritis/osteoarthritis | 206 651 (44.4) | 36 320 (50.8) | 170 331 (43.2) | <0.01 |
| Stroke/transient ischemic attack | 76 271 (16.4) | 16 611 (23.2) | 59 660 (15.1) | <0.01 |
| Ever admitted to hospital for hypoglycemia | 430 (0.092) | 103 (0.144) | 327 (0.083) | <0.01 |
| Ever treated in ED for hypoglycemia but not admitted | 1693 (0.363) | 333 (0.466) | 1360 (0.345) | 0.028 |
| Ever admitted or treated in ED for hypoglycemia | 2111 (0.453) | 431 (0.603) | 1680 (0.426) | <0.01 |
ED=emergency department.
*For comparison between patients with and without any warfarin use.
†Measured at time of first appearance in sample.